Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionDivestmentsFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Whitehawk Therapeutics (WHWK) Depreciation and Depletion: 2018-2025

Historic Depreciation and Depletion for Whitehawk Therapeutics (WHWK) over the last 6 years, with Sep 2025 value amounting to $5,600.

  • Whitehawk Therapeutics' Depreciation and Depletion fell 88.01% to $5,600 in Q3 2025 from the same period last year, while for Sep 2025 it was $131,900, marking a year-over-year decrease of 40.40%. This contributed to the annual value of $200,000 for FY2024, which is negligibly% changed negligibly from last year.
  • According to the latest figures from Q3 2025, Whitehawk Therapeutics' Depreciation and Depletion is $5,600, which was down 63.40% from $15,300 recorded in Q2 2025.
  • In the past 5 years, Whitehawk Therapeutics' Depreciation and Depletion ranged from a high of $75,000 in Q4 2023 and a low of $5,600 during Q3 2025.
  • In the last 3 years, Whitehawk Therapeutics' Depreciation and Depletion had a median value of $46,700 in 2024 and averaged $43,473.
  • In the last 5 years, Whitehawk Therapeutics' Depreciation and Depletion spiked by 31.58% in 2024 and then plummeted by 88.01% in 2025.
  • Quarterly analysis of 4 years shows Whitehawk Therapeutics' Depreciation and Depletion stood at $11,673 in 2021, then reached $75,000 in 2023, then fell by 28.00% to $54,000 in 2024, then slumped by 88.01% to $5,600 in 2025.
  • Its last three reported values are $5,600 in Q3 2025, $15,300 for Q2 2025, and $57,000 during Q1 2025.